Phase I study of definitive chemoradiotherapy with paclitaxel, CDDP and 5-FU for clinical stage IA-IIIC esophageal cancer.(PCF-RT) - Phase I study of PCF-RT

Yamamoto Sachiko0 sites24 target enrollmentFebruary 28, 2019

Overview

No summary available.

Registry

who.int

Start Date

February 28, 2019

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Yamamoto Sachiko

•1\) Histologically proven squamous cell carcinoma, or adenosquamous cell carcinoma or basaloid of the esophagus
•2\) Primary lesion are located within the cervical esophagus (Ce) and the abdominal esophagus (Ae)
•3\) Aged 20 to 75 years old
•4\) ECOG PS of 0 or 1
•5\) Clinical stage IA \- IIIC
•6\) No need for measurable lesion
•7\) No previous treatment of esophageal cancer except endoscopic surgery
•8\) No palsy of recurrent nerve
•9\) No adaptation of surgery or refused esophagectomy
•10\) Adequate organ functions

•1\) Simultaneous or metachronous double cancers, with the exception of tumor curable with therapy before diagnosis of esophageal cancer or expected cure in surgery
•2\) history of radiotherapy for mediastinum
•3\) Uncontrollable diabetes mellitus
•4\) History of myocardial infarction within 6 months, or unstable angina pectoris or cardiac function disorder
•5\) Uncontrollable arrhythmia
•6\) Patients requiring systemic steroids medication
•7\) Liver cirrhosis
•8\) Active bacterial or fungous infection
•9\) With a history of grade 2\-4 allergic reaction by CTCAE version 4\.0
•10\) With a history of grade 2\-4 nerve disturbance by CTCAE version 4\.0